ACTINIUM PHARMACEUTICALS, INC. Proceeds from Lines of Credit
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Proceeds from Lines of Credit of $390.82 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2018-03-16
- ACTINIUM PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2017-12-31 was -$49.00.
- ACTINIUM PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2017-09-30 was $49.00.
- ACTINIUM PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2017 was $390.82K.
| Period end | Proceeds from Lines of Credit 1 month | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | -$49.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $390.82K 10-K · filed 2018-03-16 | ||
| 2017-09-30 | $49.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $390.87K 10-Q · filed 2017-11-03 | |||
| 2017-06-30 | $390.82K 10-Q · filed 2017-08-04 | ||||
| 2014-04-22 | $34.73K 10-Q · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |